纯属罗列（一升一降）：
1.Abbott (NYSE: ABT) today announced that the XIENCE Xpedition((TM))
Everolimus Eluting Coronary Stent System received U.S. Food and Drug
Administration (FDA) approval and is launching immediately in the United
States, providing physicians with a next-generation technology with the
largest size matrix in the U.S. market. XIENCE Xpedition features a new
stent delivery system designed to optimize deliverability, particularly in
challenging coronary anatomies. Current: 32.94 +0.89 (2.78%) 简述：冠状动脉
治疗支架获
批。
2. Biogen Idec said its Phase 3 clinical trial for Lou Gehrig’s disease
didn’t meet its primary goals, moving the biopharmaceutical firm to
discontinue development of the drug. Shares sank 5.7% to $141.50 in
premarket trade.Current: 144.85 -5.15 (-3.43%) 简述：一个肌萎缩侧索硬化症相
关药物三期
临床效果未达到预期。
